Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

It's not a stretch to say that CSPC Pharmaceutical Group Limited's (HKG:1093) price-to-earnings (or "P/E") ratio of 10.9x right now seems quite "middle-of-the-road" compared to the market in Hong Kon

Simply Wall St22:55 ET

Changes in Hong Kong stocks | CRO concept stocks continue to decline, the Federal Reserve does not rule out possible interest rate hikes, domestic innovative drugs are still in an adjustment cycle

The Zhitong Finance App learned that CRO concept stocks continued to decline. As of press release, Tiger Pharmaceuticals (03347) fell 7.94% to HK$28.4; Kingsley Biotech (01548) fell 5.93% to HK$10.78; Kanglong Chemical (03759) fell 4.83% to HK$8.47; and Pharmaceuticals (02359) fell 4.5% to HK$32.9. According to the news, overnight, Federal Reserve officials made hawkish remarks. New York Federal Reserve Chairman Williams said that if the data reminds us that we need to raise interest rates to achieve our goals, then we will obviously do it. Furthermore, Asia

Zhitong Finance22:55 ET

Is Hansoh Pharmaceutical Group Company Limited (HKG:3692) Trading At A 23% Discount?

Key Insights The projected fair value for Hansoh Pharmaceutical Group is HK$20.45 based on 2 Stage Free Cash Flow to Equity Hansoh Pharmaceutical Group's HK$15.66 share price signals that it might b

Simply Wall St20:32 ET

China Biopharmaceutical (01177.HK): Key registration study on Class 1 innovative rovaxitinib tablets ROVADICITINIB (TQ05105) obtained positive results

Gelonghui, April 18 | China Biopharmaceutical (01177.HK) announced that the key registered clinical study of the Class 1 innovative drug Rovadicitinib (TQ05105), a class 1 innovative drug independently developed by the Group for the treatment of medium- and high-risk myelofibrosis (MF), has reached the main end. The Group has communicated with the Drug Evaluation Center (CDE) of the China National Drug Administration on the marketing application for TQ05105 tablets and obtained the CDE's approval to submit the marketing application for this product. The Group will submit a listing application for TQ05105 in the near future. TQ05105 is a group

Gelonghui FinanceApr 18 07:32 ET

China Resources Pharmaceutical (03320): Beijing Pharmaceutical has completed a transaction to transfer 100% of China Resources Zizhu's interests to China Resources Shuanghe

China Resources Pharmaceutical (03320) issued an announcement to register share transfers with relevant counterpart departments of the State Administration of Market Supervision and Administration...

Zhitong FinanceApr 18 06:42 ET

China Resources Pharmaceuticals (03320.HK) completed the proposed internal restructuring involving China Resources Zizhu

Gelonghui, April 18, 丨 China Resources Pharmaceutical (03320.HK) announced the proposed internal restructuring of China Resources Zizhu Pharmaceutical Co., Ltd. (“China Resources Zizhu”). The board of directors is pleased to announce that the share transfer registration with the relevant counterpart department of the State Administration of Market Supervision and Administration has been completed. Therefore, as of the announcement date, according to the terms of the share transfer agreement, Beijing Pharmaceutical has completed a transaction to transfer 100% of China Resources Zizhu's interests to China Resources Shuanghe.

Gelonghui FinanceApr 18 06:42 ET